Patent · US Active

Methods and compositions relating to a vaccine against prostate cancer

US8293701B2 · kind B2 · utility

0Cited by

1References

4Claims

0Family size

Assignee

CELLECTIS SA · FR

Inventors

Christoph Leder · Wendisch Evern, DE
Alan D. King · Washington, US
Maxim Pavlenko · Moscow, RU
Pavel Pisa · Järfälla, SE

Key dates

Filing date	Jun 21, 2006
Grant date	Oct 23, 2012
Priority date	—
Expiry date	Mar 20, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2239/58
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An object of the invention is to provide methods and compositions relating to a vaccine against prostate cancer which includes a non-human-primate PSA for administration to humans to provide an immune response against human PSA. More generally, an object of the invention is to provide methods and compositions relating to using a non-human primate xenogeneic antigen (e.g. protein) in a human, wherein, with respect to the non-human primate xenogeneic antigen that is used, there are relatively few interspecies differences between the non-human primate xenogeneic antigen and the human self antigen in order to induce an optimal immune response in the human to its native self antigen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.